Johnson & Johnson remains locked in a bitter fight with lawyers opposing its third attempt to settle tens of thousands of lawsuits through a controversial bankruptcy-court maneuver. The women alleging J&J’s talc products caused their cancer are caught in the crossfire. (Reuters)

Concern over President Joe Biden’s fitness for a second term has left some voters and politicians pushing him to undergo a cognitive test. Yet one test wouldn’t provide a final word on the president’s cognitive abilities, doctors said. Doctors would have to conduct further evaluation, including commissioning more tests like a PET scan. (The Wall Street Journal)

GLP-1 drugs like Ozempic and Wegovy may lower the risk of certain obesity-related cancers, a recent study suggested. Patients who took GLP-1 drugs as opposed to insulin saw a significant reduction in 10 of 13 obesity-related cancers — including esophageal, colorectal, endometrial, gallbladder, liver, ovarian, kidney and pancreatic cancer. (MM+M)

HilleVax’s stock fell 89% after the company announced the discontinuation of the development of a vaccine against norovirus for infants. The vaccine failed to meet the main goal of the Stage 2b  study after displaying a mere 5% efficacy rate. (MarketWatch)

A recent study of CAR-T cell therapies published in Nature Medicine found that more than half of non-relapse cancer patient deaths are due to infection. Among the infection-related deaths just over half were due to COVID-19, however, when researchers looked at non-relapse deaths before COVID, there was not a large shift in mortality. (Endpoints News)

Click here to view yesterday’s Five things for pharma marketers to know.